Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State*
暂无分享,去创建一个
[1] N. Donato,et al. Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells. , 2008, Blood.
[2] P. Gopalakrishnakone,et al. Proteomic analysis of the venom of Heterometrus longimanus (Asian black scorpion) , 2008, Proteomics.
[3] C. Récher,et al. A critical role for Lyn in acute myeloid leukemia. , 2008, Blood.
[4] J. Schneider,et al. Csk-binding Protein Mediates Sequential Enzymatic Down-regulation and Degradation of Lyn in Erythropoietin-stimulated Cells* , 2006, Journal of Biological Chemistry.
[5] Matthew B. Wilson,et al. Src Family Kinases Phosphorylate the Bcr-Abl SH3-SH2 Region and Modulate Bcr-Abl Transforming Activity* , 2006, Journal of Biological Chemistry.
[6] Susan O'Brien,et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.
[7] M. Wittekind,et al. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. , 2006, Cancer research.
[8] Donna Neuberg,et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.
[9] W. Erber,et al. Lyn deficiency reduces GATA-1, EKLF and STAT5, and induces extramedullary stress erythropoiesis , 2005, Oncogene.
[10] C. Quilici,et al. Perturbed myelo/erythropoiesis in Lyn-deficient mice is similar to that in mice lacking the inhibitory phosphatases SHP-1 and SHIP-1. , 2004, Blood.
[11] Ping Chen,et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.
[12] A. Gewirtz,et al. Short interfering RNA (siRNA) targeting the Lyn kinase induces apoptosis in primary, and drug-resistant, BCR-ABL1(+) leukemia cells , 2004, Nature Medicine.
[13] J. Parsons,et al. Src family kinases, key regulators of signal transduction , 2004, Oncogene.
[14] Ping Chen,et al. Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.
[15] J. Drachman,et al. Lyn tyrosine kinase regulates thrombopoietin-induced proliferation of hematopoietic cell lines and primary megakaryocytic progenitors. , 2004, Blood.
[16] S. Ben‐Sasson,et al. Lyn Is a Target Gene for Prostate Cancer , 2004, Cancer Research.
[17] D. Fabbro,et al. Dual-specific Src and Abl kinase inhibitors, PP1 and CGP76030, inhibit growth and survival of cells expressing imatinib mesylate-resistant Bcr-Abl kinases. , 2003, Blood.
[18] N. Donato,et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. , 2003, Blood.
[19] D. Boschelli,et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. , 2003, Cancer research.
[20] Matthew B. Wilson,et al. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr–Abl signal transduction and oncogenesis , 2002, Oncogene.
[21] S. Rane,et al. JAKs, STATs and Src kinases in hematopoiesis , 2002, Oncogene.
[22] D. Chappell,et al. Thyroid Hormone Receptor-interacting Protein 1 Modulates Cytokine and Nuclear Hormone Signaling in Erythroid Cells* , 2001, The Journal of Biological Chemistry.
[23] D. Fisher,et al. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. , 2001, Cancer research.
[24] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[25] J. Williams,et al. Maturation of erythroid cells and erythroleukemia development are affected by the kinase activity of Lyn. , 2001, Cancer research.
[26] F. Giancotti,et al. Neutral endopeptidase inhibits prostate cancer cell migration by blocking focal adhesion kinase signaling. , 2000, The Journal of clinical investigation.
[27] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[28] L. Toledo,et al. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.
[29] T. Pawson,et al. Protein-protein interactions define specificity in signal transduction. , 2000, Genes & development.
[30] S. Klinken,et al. HS1 Interacts with Lyn and Is Critical for Erythropoietin-induced Differentiation of Erythroid Cells* , 2000, The Journal of Biological Chemistry.
[31] J. Kuriyan,et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.
[32] S. Harrison,et al. Crystal structures of c-Src reveal features of its autoinhibitory mechanism. , 1999, Molecular cell.
[33] N. Miyasaka,et al. Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathway. , 1998, Blood.
[34] C. Deberry,et al. Lyn Associates with the Juxtamembrane Region of c-Kit and Is Activated by Stem Cell Factor in Hematopoietic Cell Lines and Normal Progenitor Cells* , 1997, The Journal of Biological Chemistry.
[35] S. Klinken,et al. Lyn tyrosine kinase is essential for erythropoietin‐induced differentiation of J2E erythroid cells , 1997, The EMBO journal.
[36] John Kuriyan,et al. Crystal structure of the Src family tyrosine kinase Hck , 1997, Nature.
[37] Michael J. Eck,et al. Three-dimensional structure of the tyrosine kinase c-Src , 1997, Nature.
[38] O. Olivieri,et al. Deficiency of Src family kinases Fgr and Hck results in activation of erythrocyte K/Cl cotransport. , 1997, The Journal of clinical investigation.
[39] Hiroto Yamaguchi,et al. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation , 1996, Nature.
[40] S. Stacker,et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease , 1995, Cell.
[41] E. Ingley,et al. Src family kinases: regulation of their activities, levels and identification of new pathways. , 2008, Biochimica et biophysica acta.
[42] S. Corey,et al. Src-related protein tyrosine kinases in hematopoiesis. , 1999, Blood.